Laure Vincent

Sep 25, 2024 | nature.com | Maria-Victoria Mateos |Katja Weisel |Valerio De Stefano |Hartmut Goldschmidt |Laure Vincent |Aurore Perrot | +2 more

AbstractTreatment of relapsed/refractory multiple myeloma (RRMM) is challenging as patients exhaust all available therapies and the disease becomes refractory to standard drug classes. Here we report the final results of LocoMMotion, the first prospective study of real-world clinical practice (RWCP) in triple-class exposed (TCE) patients with RRMM, with a median follow-up of 26.4 months (range, 0.1–35.0). Patients (N  =  248) had received median 4 prior LOT (range, 2–13) at enrollment.